Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804603 · ClinicalTrials.gov registry record · Phase 2
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
A Phase 2 study of Obesity, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 3
- Study locations
NCT06804603 is a Phase 2 study of Obesity that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 124 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06804603, a Phase 2 study of Obesity, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tradipitant
Study Locations (3)
California
- Vanda Investigational Site - Los Angeles
Minnesota
- Vanda Investigational Site - Rochester
New York
- Vanda Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2025-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06804603
The ClinicalTrials.gov registry entry for NCT06804603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06804603 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06804603 about?
NCT06804603 is a clinical study titled "A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use". The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
What is the current status of trial NCT06804603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2025-02-25. Estimated completion is 2025-10-06.
What conditions does trial NCT06804603 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06804603?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT06804603?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804603 being conducted?
This trial has 3 study locations across California, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.